PolyMedix, Inc. Logo

PolyMedix to Review Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic

Conference Call Scheduled for Wednesday, December 7th at 9:00 AM

| Source: PolyMedix, Inc.

RADNOR, Pa., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, has scheduled a conference call and webcast for Wednesday, December 7 at 9:00 AM Eastern Time. At that time, management will review the results of the interim analysis from the ongoing Phase 2 clinical study with PMX-30063, defensin-mimetic antibiotic in treating patients with Staph Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This is the first clinical study ever conducted in patients with Staph infections with this new class of antibiotic – a defensin-mimetic.

Participants may access this audio webcast through a live broadcast on the Company's website at www.polymedix.com or http://www.investor.polymedix.com/eventdetail.cfm?eventid=106055. Participants should log onto the audio webcast at least 15 minutes prior to the call. The Internet presentation will be available for up to 90 days after the call at the Company's website.

The call in number is 877-771-7024. The international call in number is 678-905-9379. A replay of the conference call will be available two hours after the call's completion and remain available for seven days. The replay number to hear the conference call is 855-859-2056 or 404-537-3406. The passcode is 30580442.

About PMX-30063

PolyMedix's novel antibiotic compound, PMX-30063, is the first of a new class of antibiotics – defensin-mimetics. PMX-30063 is a small-molecule designed to mimic the activity of human host-defense proteins (HDPs), the body's natural defense against bacterial infections. HDPs kill bacteria by directly targeting bacterial membranes and disrupting them. Widespread resistance to this mechanism of action has not developed despite millions of years of evolution. With PMX-30063 designed to mimic HDPs, we believe that resistance is also unlikely to evolve to this novel antibiotic, making PMX-30063 a potential solution to the growing problem of bacterial resistance. PMX-30063 has been tested in three Phase 1 clinical studies and is currently in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections caused by S. aureus bacteria.

About PolyMedix, Inc.

PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. PolyMedix has a pipeline of novel infectious disease and cardiovascular product candidates, all of which were internally developed using a proprietary drug discovery platform. The lead compound in PolyMedix's infectious disease program is PMX-30063, a new class of antibiotic – a defensin-mimetic – designed to mimic first-line human innate immunity, or host defense proteins. This innovative approach utilizes the same mechanism of action that evolved in nature which higher life forms use to protect themselves from bacteria. Having the same mechanism of action as the host defense proteins, PMX-30063 is designed to directly address one of the most significant issues in infectious disease today – drug resistance, which is believed to be much less likely to develop with PMX-30063. PMX-30063 is currently in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus bacteria, including methicillin-resistant S. aureus (MRSA). PolyMedix is also leveraging its antimicrobial expertise with the PolyCides®, antimicrobial additives to materials, such as cosmetics, plastics and textiles, to create self-sterilizing products and surfaces. The lead compound in PolyMedix's cardiovascular program is PMX-60056, which is designed to restore coagulation and mitigate bleeding in certain interventional cardiology procedures, such as Percutaneous Coronary Intervention (PCI) and Coronary Artery Bypass Surgery (CABG), as well as treat bleeding in emergency situations. PMX-60056 has met safety and efficacy endpoints in four clinical trials conducted to date demonstrating clinical proof of concept. PMX-60056 is currently in a Phase 2 clinical trial in patients undergoing PCI and in a Phase 1B/2 dose ranging clinical trial in subjects receiving the low molecular weight heparin enoxaparin. For more information, please visit our website at www.polymedix.com.

The PolyMedix, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10449

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedix's need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Lisa Caperelli
Director, Investor Relations & Corporate Communications